Antisense oligonucleotide therapy for proline-23-histidine autosomal dominant retinitis pigmentosa
Sign Up to like & getrecommendations! Published in 2023 at "Current Opinion in Ophthalmology"
DOI: 10.1097/icu.0000000000000947
Abstract: Purpose of review To discuss antisense oligonucleotide (ASON) therapy for autosomal dominant retinitis pigmentosa (adRP) caused by the proline-23-histidine (P23H) mutation in the rhodopsin gene. Recent findings Viral and nonviral therapies to treat adRP are… read more here.
Keywords: antisense oligonucleotide; retinitis pigmentosa; therapy; proline histidine ... See more keywords